Video posted Sept 2018 - Dr. Steensma
Posted: Sun Oct 14, 2018 6:40 pm
Smiley faces added 
(Staying positive)
(Editor removals ~~Your message contains too many smilies. The maximum number of smilies allowed is 1.~~ God Bless Fish, he ran a tight ship,,, I replaced with Astericks, smiley face emoticon with exclamation point!)
https://www.vjhemonc.com/video/g7alpq7r ... ls-in-mds/
SOHO 2018 | Promising approaches and clinical trials in MDS
David Steensma
A number of promising therapeutic approaches are under investigation for the treatment of myelodysplastic syndromes (MDS). We got on update on these exciting developments from David Steensma, MD, of the Dana-Farber Cancer Institute, Boston, MA, at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX. Dr Steensma highlights the potential combination of hypomethylating agents with immunotherapies such as checkpoint inhibitors, or the BCL2 inhibitor venetoclax. *He also expresses his excitement for the telomerase inhibitor imetelstat* and APR-246, which targets p53, before briefly mentioning the potential for CAR T-cells in MDS.
https://www.vjhemonc.com/video/edlwvahg ... treatment/
SOHO 2018 | Current landscape and future directions for lower-risk MDS treatment
David Steensma
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, David Steensma, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the current treatment landscape for lower-risk myelodysplastic syndromes (MDS), as well as future directions for therapy. Dr Steensma highlights how the majority of low-risk MDS patients are treated with hematopoietic growth factors or lenalidomide, although certain patients will respond to immunosupressants and hypomethylating agents. He expresses his hopes for the potential of luspatercept, a recombinant fusion protein, *as well as oral hypomethylating agents, the telomerase inhibitor imetelstat* and splicing inhibitors.
(Staying positive)(Editor removals ~~Your message contains too many smilies. The maximum number of smilies allowed is 1.~~ God Bless Fish, he ran a tight ship,,, I replaced with Astericks, smiley face emoticon with exclamation point!)
https://www.vjhemonc.com/video/g7alpq7r ... ls-in-mds/
SOHO 2018 | Promising approaches and clinical trials in MDS
David Steensma
A number of promising therapeutic approaches are under investigation for the treatment of myelodysplastic syndromes (MDS). We got on update on these exciting developments from David Steensma, MD, of the Dana-Farber Cancer Institute, Boston, MA, at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX. Dr Steensma highlights the potential combination of hypomethylating agents with immunotherapies such as checkpoint inhibitors, or the BCL2 inhibitor venetoclax. *He also expresses his excitement for the telomerase inhibitor imetelstat* and APR-246, which targets p53, before briefly mentioning the potential for CAR T-cells in MDS.
https://www.vjhemonc.com/video/edlwvahg ... treatment/
SOHO 2018 | Current landscape and future directions for lower-risk MDS treatment
David Steensma
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, David Steensma, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the current treatment landscape for lower-risk myelodysplastic syndromes (MDS), as well as future directions for therapy. Dr Steensma highlights how the majority of low-risk MDS patients are treated with hematopoietic growth factors or lenalidomide, although certain patients will respond to immunosupressants and hypomethylating agents. He expresses his hopes for the potential of luspatercept, a recombinant fusion protein, *as well as oral hypomethylating agents, the telomerase inhibitor imetelstat* and splicing inhibitors.